All News

2020

July

SARS-CoV-2, the novel coronavirus at the root of the COVID-19 pandemic
Story / Jul 09, 2020

Cancer didn’t stop for COVID-19

Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.

Read More
Media Release / Jul 07, 2020

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU

Read More
Media Release / Jul 02, 2020

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies

Read More
Media Release / Jul 01, 2020

Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case

Read More

June

Media Release / Jun 29, 2020

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14

Read More
Media Release / Jun 29, 2020

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options

Read More
Media Release / Jun 26, 2020

Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile

Read More
Media Release / Jun 26, 2020

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

Read More
Media Release / Jun 25, 2020

Novartis Resolves Legacy FCPA Investigations

Read More
Media Release / Jun 25, 2020

Novartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More